Egrifta (Tesamorelin) + GHK-Cu Stack: When to Pick One Over Both

Do the two overlap at all?

Tesamorelin is a synthetic analog of human growth hormone-releasing factor: the 44-amino-acid human sequence with a hexenoyl group on its N-terminal tyrosine [1]. It binds GRF receptors on pituitary somatotroph cells and stimulates release of the body's own growth hormone, which raises IGF-1 and IGFBP-3 [1].

GHK-Cu is the copper complex of a three-amino-acid peptide found in human plasma, saliva and urine [9]. Its proposed actions (collagen and proteoglycan synthesis, metalloproteinase modulation, attracting immune and endothelial cells to an injury) come from laboratory and animal work in dogs, rats, mice and pigs [9].

None of the trials cited here measured how the combination affects IGF-1, glucose, skin or collagen outcomes. The interaction sections of the Egrifta labels cover CYP450-metabolized drugs and glucocorticoids, and do not mention copper peptides [1][6]. That is not a finding of safety.

Tesamorelin: one approved use, and how strong the data are

The label covers one thing: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Egrifta is not indicated for weight loss, and the label describes its effect on weight as neutral; long-term cardiovascular safety has not been established [1].

In the 412-patient trial reported by Falutz et al. in 2007, tesamorelin 2 mg daily for 26 weeks cut visceral adipose tissue by 15.2% while placebo rose 5.0%, with triglycerides down 50 mg/dL versus up 9 mg/dL and IGF-1 up 81.0% versus down 5.0% [2]. Pooled across the two phase 3 trials (806 patients, 543 on tesamorelin and 263 on placebo), visceral fat changed -24 versus +2 cm2, a treatment effect of -15.4%, with no significant change in subcutaneous abdominal fat [10].

The visceral fat effect tracks with continued treatment. In the extension phases, people switched from tesamorelin to placebo regained fat (a mean +22% in one study and +16% in the other between week 26 and week 52), while those who stayed on tesamorelin changed 0% and -5% [1].

There is some randomized evidence outside HIV lipodystrophy. A 12-month placebo-controlled trial in 60 abdominally obese adults with reduced GH secretion found visceral fat -16 cm2 versus +19 cm2 on placebo (treatment effect -35 cm2) with no significant change in fasting glucose, 2-hour glucose or HbA1c [11]. That is one small trial, and it is not an approved use.

GHK-Cu: what is actually known in humans

No FDA-approved drug is known to contain GHK-Cu [3]. It is not the same as copper histidinate (Zycubo), which was approved for Menkes disease in children in January 2026 and is a different compound [12].

The human evidence is small and topical. In an 86-patient randomized, evaluator-blinded trial in venous stasis ulcers, a 0.4% tripeptide copper complex cream was no different from an inert vehicle for ulcer size, while silver sulfadiazine 1% reduced it [4]. In a randomized trial of 13 patients who had CO2 laser resurfacing around the mouth, computer analysis and blinded evaluators found no difference in redness resolution, wrinkles or overall skin quality; only a patient questionnaire favored GHK-Cu (P=.04) [5]. A 1994 randomized, evaluator-blinded trial in diabetic neuropathic foot ulcers did report faster closure with a topical GHK-Cu gel, with a median 98.5% area closure versus 60.8% for vehicle [13].

A 2026 systematic review kept 64 records from 1,247 and concluded that the human literature remains thin and fragmented: most randomized trials are small, use facial cosmetic creams, and microneedle delivery has not been tested in a single registered, adequately powered human trial [14].

The regulatory split matters. Cosmetics and cosmetic ingredients, other than color additives, do not need FDA approval before they are sold [8]. Whether a product is a cosmetic or a drug depends on its intended use, and claims to treat disease or affect body structure or function can make it a drug [8]. Injectable GHK-Cu is not a cosmetic and is not FDA-approved. FDA's page on bulk substances that may raise significant safety risks lists injectable GHK-Cu in its table of nominations withdrawn by the nominators, noting that compounded injectable drugs containing it 'may pose risk for immunogenicity' and that there are 'limited data in humans to inform safety-related considerations' [15]. Non-injectable GHK-Cu sits in category 1 of FDA's list for state-licensed pharmacies, the group under evaluation for the compounding bulks list, and FDA says it intends to consult its Pharmacy Compounding Advisory Committee about the substance before the end of February 2027 [3][16].

Which one fits which goal

• The goal is the labeled one: excess abdominal fat in HIV lipodystrophy. Tesamorelin is the only agent here with phase 3 randomized data for that endpoint [1][2][10].
• The goal is skin appearance or a healing wound. Topical copper peptide is the relevant product, with mixed and small trial results: one study favored it on a questionnaire, one found no difference in venous ulcers, one found faster closure in diabetic foot ulcers [5][4][13].
• The goal is injectable GHK-Cu for body composition or systemic effect. There is no FDA-approved product or dose, and FDA has flagged immunogenicity risk for the injectable route [3][15].
• The goal is both at once. No trial cited here tested them together, so neither the labels nor the studies speak to the combination.

What the Egrifta labels say to watch

IGF-1: among people treated for 26 weeks, 47% had IGF-1 above 2 standard deviation scores and 36% above 3 SDS, with the effect seen as early as week 13; at 52 weeks, 34% and 23% [1]. The label calls the effects of prolonged IGF-1 elevation unknown, says to monitor IGF-1, and says to consider discontinuing when levels stay elevated (for example above 3 SDS), particularly if the fat-loss response is not robust [1].

Glucose: HbA1c of 6.5% or higher developed in 5% of tesamorelin patients versus 1% on placebo by week 26, a hazard ratio of about 3.3 (95% CI 1.4 to 9.6). The label says to evaluate glucose before starting and to monitor periodically during treatment [1].

Injection-site reactions occurred in 25% on tesamorelin versus 14% on placebo in the first 26 weeks. Hypersensitivity reactions occurred in 4% (itching, redness, flushing, hives, rash), and the label advises seeking prompt medical attention and discontinuing if one is suspected. Arthralgia was 13% versus 11%, peripheral edema 6% versus 2%, and myalgia 6% versus 2% [1].

Contraindications are disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation or head trauma), active malignancy, known hypersensitivity to tesamorelin or its excipients, and pregnancy [1][6].

One interaction is easy to miss. The label explains that growth hormone inhibits the enzyme that converts cortisone and prednisone to their active forms, and says people on glucocorticoid replacement for hypoadrenalism may need higher maintenance or stress doses after starting tesamorelin [1]. The label also says to monitor for interactions with drugs metabolized by CYP450 enzymes [1].

Regulatory and sport status in one place

Tesamorelin is an FDA-approved prescription drug first approved on November 10, 2010; the current labels are Egrifta SV and Egrifta WR, both dated July 29, 2026 [17][1][6]. It appears in no category on FDA's compounding lists for state-licensed pharmacies or outsourcing facilities, and FDA has made no category-based statement about compounding it [3][18]. Compounded drugs are not FDA-approved, since FDA does not review their safety, effectiveness or quality before marketing [19].

WADA names tesamorelin in S2.2.4 of its Prohibited List (growth hormone releasing factors) and prohibits it at all times, in and out of competition [7]. GHK-Cu is not named on the 2026 or 2027 List, but WADA's 2027 explanatory notes say peptides not specifically named may still be prohibited, so the List alone does not settle it [7][20].